Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) FCF Margin (2016 - 2025)

Historic FCF Margin for Zevra Therapeutics (ZVRA) over the last 9 years, with Q3 2025 value amounting to 15.92%.

  • Zevra Therapeutics' FCF Margin rose 5062200.0% to 15.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 28.7%, marking a year-over-year increase of 2556300.0%. This contributed to the annual value of 295.04% for FY2024, which is 1718400.0% down from last year.
  • Per Zevra Therapeutics' latest filing, its FCF Margin stood at 15.92% for Q3 2025, which was up 5062200.0% from 14.73% recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' FCF Margin registered a high of 137.88% during Q2 2021, and its lowest value of 490.3% during Q3 2024.
  • Its 5-year average for FCF Margin is 158.17%, with a median of 128.27% in 2023.
  • Per our database at Business Quant, Zevra Therapeutics' FCF Margin tumbled by -4547200bps in 2022 and then skyrocketed by 5062200bps in 2025.
  • Over the past 5 years, Zevra Therapeutics' FCF Margin (Quarter) stood at 33.5% in 2021, then crashed by -564bps to 222.35% in 2022, then surged by 44bps to 125.62% in 2023, then dropped by -8bps to 135.28% in 2024, then soared by 112bps to 15.92% in 2025.
  • Its FCF Margin was 15.92% in Q3 2025, compared to 14.73% in Q2 2025 and 40.79% in Q1 2025.